Live tape
Top 8, mentions 7d16,898MSFT3,212 mentions▲ +0.08GOOGL2,592 mentions▲ +0.05META2,186 mentions▲ +0.04AAPL2,005 mentions▲ +0.07SPCX1,977 mentions▲ +0.06SNDK1,801 mentions▲ +0.06NVDA1,725 mentions▲ +0.07QQQ1,400 mentions▲ +0.04

Equity · Healthcare

CLDX

Celldex Therapeutics, Inc. · NasdaqCM

$35.60 −0.14% 1D Finazon · prior-day close · Jul 28, 2026
Price · Chart Chart by TradingView
Track this symbol on TradingView

The chart above plots the price of CLDX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 62 sessions over that window: $32.30 on 1 May 2026 through $35.60 on 28 July 2026. Finazon · prior-day close.

Market cap $2.8B
52-week range $19.66 – $39.89
Avg volume 252.0K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Jul 29, 2026

CLDX insider trades

SEC Form 4

CLDX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 2 January 2026.

Date Insider Type Shares Value
04 Dec 2025 Jimenez Freddy A. SVP & GENERAL COUNSEL Sell 4,166 $121K
13 Nov 2025 Wright Richard M. Sell 49,298 $1.18M
13 Aug 2025 Jimenez Freddy A. SVP & GENERAL COUNSEL Sell 771 $19K
Compensation mechanics (4 filings)

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
02 Jan 2026 Martin Samuel Bates SVP AND CFO Option exercise 4,817 $50K
15 Dec 2025 PEPIN RONALD SR. VP & CBO Option exercise 19,333 $106K
13 Nov 2025 Wright Richard M. Option exercise 49,298 $693K
10 Nov 2025 Lawver Teri L SVP & Chief Commercial Officer Award 100,000

CLDX reported financials

SEC EDGAR XBRL

CLDX reported revenue of $1.5M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$258.8M.

Figure Reported Period
Revenue $1.5M 31 Dec 2025 fiscal year
Net income −$258.8M 31 Dec 2025 fiscal year
Diluted EPS −$3.90 31 Dec 2025 fiscal year
Total assets $511.3M 31 Mar 2026 at period end
Total equity $456.2M 31 Mar 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 31 Mar 2026

CLDX earnings

SEC EDGAR
Date Period EPS Revenue
31 Mar 2026 Q1 2026 $-1.18 —
31 Dec 2025 FY 2025 $-3.90 —
30 Sep 2025 Q3 2025 $-1.01 —
30 Jun 2025 Q2 2025 $-0.85 —

Reported figures & scheduled dates · SEC EDGAR filings

CLDX institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a CLDX position for the quarter ended 31 Mar 2026 — a combined $211.9M; the latest of those filings landed 15 May 2026.

Fund Action Shares Value
Point72 Asset Management Added +83.7% shares 3,229,939 $102.5M
Millennium Management Held (±25%) +3.4% shares 1,253,532 $39.8M
Fisher Asset Management Held (±25%) +8.2% shares 1,013,648 $32.2M
Baker Bros. Advisors Held (±25%) 665,370 $21.1M
Citadel Advisors Added +264.1% shares 200,612 $6.4M
Two Sigma Investments Held (±25%) +3.4% shares 137,015 $4.3M
Balyasny Asset Management New position 85,026 $2.7M
D. E. Shaw & Co. Trimmed −61.2% shares 52,860 $1.7M
Tudor Investment Corp New position 35,393 $1.1M
AQR Capital Management New position 7,777 $247K

Source: SEC EDGAR 13F filings

CLDX fails-to-deliver

SEC CNS data

On 30 Jun 2026, 10,049 shares of CLDX failed to deliver (about $376K) — the latest of 3 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
30 Jun 2026 10,049 $376K 0.013%
29 Jun 2026 6,763 $238K 0.009%
26 Jun 2026 3 $102 <0.001%
24 Jun 2026 2,832 $93K 0.004%

Source: SEC fails-to-deliver (CNS) data